חוב כולל להון LivaNova PLC (LIVN)

Patents and FDA approvals protect the unique neurostimulators and circulation systems of LivaNova PLC (LIVN), blocking access for new startups. The business relies on sustained dominance in niche cardiac surgery segments where strict regulations curb competition. This price chart on GURU.Markets clearly demonstrates the 0.29 metric, confirming the status of an authoritative brand whose ultra-reliable technologies enjoy the unconditional trust of leading surgeons.

When selecting defensive assets, low debt leverage becomes the priority, which for LivaNova PLC (LIVN) is evidenced by investments in strategic component reserves and the diversification of electronics suppliers. Analyzing total liabilities relative to equity within the company's financial leverage history allows for an assessment of the business's dependence on borrowed funds and the bankruptcy risks associated with a cooling of demand.